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uclear factor of activated T cell (NFAT) is a ubiquitous
regulator involved in multiple biological processes.
Here, we demonstrate that NFAT is temporally re-
quired in the developing atrial myocardium between embry-
onic day 14 and P0 (birth). Inhibition of NFAT activity by
conditional expression of dominant-negative NFAT causes
thinning of the atrial myocardium. The thin myocardium
N
 
exhibits severe sarcomere disorganization and reduced
expression of cardiac troponin-I (cTnI) and cardiac troponin-T
(cTnT). Promoter analysis indicates that NFAT binds to and
regulates transcription of the cTnI and the cTnT genes.
Thus, regulation of cytoskeletal protein gene expression by
NFAT may be important for the structural architecture of
the developing atrial myocardium.
 
Introduction
 
The heart is the first organ to develop after completion of
gastrulation, which occurs at around embryonic day (E)* 7.5
(Kaufman, 1992; Harvey and Rosenthal, 1999; Kaufman
and Bard, 1999). During early morphogenesis, endocardium
and myocardium, in conjunction with a middle layer of
“cardiac jelly,” form a simple heart tube. Subsequent folding,
remodeling, and septation turn the linear heart tube into a
four-chambered heart. These processes involve multiple
transcription factors and signaling pathways (Sucov, 1998;
MacLellan and Schneider, 2000; Srivastava, 2001). Later
cell proliferation, wall thickening, and trabeculation of the
myocardium lead to a mature, functional heart. However,
molecular processes that are involved in late morphogenesis
of heart maturation remain to be identified.
The transcription factor, nuclear factor of activated T cells
(NFAT), was first identified as an important regulator for
interleukin (IL)-2 gene expression (Durand et al., 1988).
Subsequent reports indicate that NFAT is involved in multiple
biological processes, including cardiac and skeletal muscle
hypertrophy, adipocyte differentiation, and memory and
plasticity (Ho et al., 1998; Molkentin et al., 1998; Graef et
al., 1999; Yang et al., 2002). To understand NFAT functions,
dominant-negative NFAT (dnNFAT) inhibitors have been
generated (Northrop et al., 1994; Aramburu et al., 1998;
Chow et al., 1999; Miskin et al., 2000; Saneyoshi et al.,
2002). The dnNFAT interferes with targeting of calcineurin
without affecting the phosphatase catalytic activity. Transgenic
expression of dnNFAT in the thymus blocks endogenous
NFAT functions, such as IL-2 expression (Chow et al., 1999).
Therefore, dnNFAT allows examination of the consequences
of reduced NFAT activity in physiologically relevant models.
Previous papers have shown that targeted disruption of
NFATc1 impairs heart valve and septum formation, and
hence causes embryonic lethality (de la Pompa et al., 1998;
Ranger et al., 1998). Heart valves are originated from endocar-
dial cushion tissue (Harvey and Rosenthal, 1999; Kaufman
and Bard, 1999), and immunofluorescence analysis has
shown that NFATc1 is expressed transiently in this tissue.
These reports indicate a specific spatial and temporal require-
ment for NFATc1 function. Although these reports are relevant
for understanding one role of NFAT in heart development,
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functions of NFAT in other cell types that are also impor-
tant for heart function remain elusive. For example, cardiac
myocytes are critical for maintaining the structural integrity
of the heart and generating mechanical force for circulation.
In diseased hearts, cardiac myocytes respond to an increased
demand for output and become hypertrophic; a common
early sign of heart failure. NFAT has been demonstrated to
play an important role in cardiac hypertrophy (Molkentin et
al., 1998; Sussman et al., 1998; Rothermel et al., 2001; Zou
et al., 2001). Thus, the role of NFAT in myocardium must
be thoroughly examined because it may provide knowledge
and insights into new drugs and therapies for conditions as-
sociated with hypertrophy and cardiac dysfunction.
The purpose of this paper is to examine the role of NFAT
in developing cardiac myocytes. Here, we report that there is
a temporal requirement of NFAT in the developing myocar-
dium. Inhibition of NFAT causes a severe defect in the cy-
toskeletal structure and reduced expression of cardiac tropo-
nin-I (cTnI) and cardiac troponin-T (cTnT). Thus, NFAT
is required for proper cardiac myocyte development.
 
Results
 
Subcellular distribution of NFAT 
in developing myocardium
 
To investigate the role of NFAT in the developing myo-
cardium, we examined the subcellular distribution of
NFAT (Fig. 1 A). Immunofluorescence analysis revealed that
NFAT was located in the cytoplasm and was not detected in
the nucleus of the developing cardiomyocytes at E14. At
E16, NFAT was detected in both the nucleus and the cyto-
plasm. At E18, staining of nuclear NFAT was diminished,
suggesting nuclear export has begun. At P0, NFAT was not
detected in the nucleus. Quantitation of nuclear intensity
also revealed temporal NFAT nuclear localization (Fig. 1 B).
These data indicate that NFAT is translocated into the nu-
cleus after E14 and exported by P0.
 
Expression of dnNFAT blocks NFAT 
nuclear localization
 
To examine whether NFAT regulates gene expression in de-
veloping cardiomyocytes, we have generated heart-specific,
tetracycline-inducible dnNFAT transgenic mice (Fig. 2 A).
The 
 
 
 
-myosin heavy chain (MHC
 
 
 
) promoter was used to
express the reverse tetracycline regulator (a tet-on system)
because the spatial and temporal expression of MHC
 
 
 
 in
the developing and adult heart is well characterized (Lyons
et al., 1990; Ng et al., 1991; Subramaniam et al., 1991;
Buckingham et al., 1992). The MHC
 
 
 
 promoter drives
strong expression of the transgene in the developing atria
and, to a lesser extent, in the developing ventricles. The tet-
on inducible system was chosen because the kinetics for
transgene induction is more responsive as compared with
the tet-off scheme (Kistner et al., 1996; Gingrich and Roder,
1998). Thus, the temporal requirement of NFAT in devel-
oping atrial myocardium would be closely represented.
To induce expression of dnNFAT, doxycycline (Dox; a
potent analogue of tetracycline)-treated water was given to
transgenic-positive (Tg
 
 
 
) mice and wild-type (Wt) non-
transgenic littermate controls. Administration of Dox in-
duced expression of dnNFAT in Tg
 
 
 
, but not Wt, mice
(Fig. 2 A). Importantly, dnNFAT was detected only in the
presence of Dox. Immunofluorescence analysis further re-
vealed that administration of Dox induced dnNFAT expres-
sion and blocked NFAT nuclear accumulation in the devel-
oping atria (Fig. 2, B and C). However, low expression of
dnNFAT in the developing ventricles was not sufficient to
block NFAT nuclear localization. These data indicate that
conditional expression of dnNFAT provides an effective
means to examine the temporal requirement of NFAT in the
developing atrial myocardium.
Figure 1. Subcellular distribution of NFAT in developing atria. 
Subcellular distribution of NFAT in developing mouse atria was 
examined by immunofluorescence analysis (A). At E14, NFAT was 
not detected in the nucleus (arrowheads) as indicated by the separated 
staining of NFAT (green) and the nuclei (red; see inset for higher 
magnification). At E16, nuclear NFAT was observed, as indicated by 
the overlapped staining of NFAT and the nuclei (yellow). At E18, a 
weaker staining of nuclear NFAT was observed, suggesting that 
some nuclear export has occurred. At birth (P0), little nuclear NFAT 
was detected as indicated by the separated staining of NFAT (green) 
and the nuclei (red). The relative intensity of nuclear NFAT in the 
developing atria is presented (B). Bar, 30  m.T
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Figure 2. Expression of dnNFAT blocks NFAT nuclear localization. (A) Schematic representation of constructs for the transgene creation. 
Expression of tetracycline regulator (rtTA) is driven by the heart-specific  -MHC promoter. Expression of FLAG epitope-tagged dnNFAT is 
regulated by the Tet-responsive promoter. Co-injection of both constructs generates heart-specific, tet-inducible expression of dnNFAT. 
Expression of dnNFAT in Wt and Tg  hearts, in the presence ( ) or absence ( ) of Dox, was examined by immunoblotting analysis using 
the M2 mAb that recognizes the FLAG epitope. (B and C) Subcellular distribution of NFAT in Wt and Tg  E16 heart was examined by 
immunofluorescence analysis. Expression of dnNFAT (blue) in Wt and Tg  atria (A), in the presence ( ) or absence ( ) of Dox, was examined 
using the M2 mAb. Co-localization (yellow) of NFAT in the nuclei (arrowheads) was observed in Wt atria (B). Expression of dnNFAT blocks 
nuclear translocation, and thus separated staining of NFAT (green) and the nuclei (red) was observed in Dox-treated Tg  atria. Localization of 
NFAT and the expression of dnNFAT in the ventricles (V) were also shown. The relative intensity of nuclear NFAT in Wt and Tg  atria are 
presented (C). Bars, 30  m.T
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Inhibition of NFAT causes thinning 
in the developing myocardium
 
To examine the role of NFAT in the developing myocar-
dium, timed-pregnant mice were given Dox-treated or un-
treated plain water starting on E0.5, continuing until the
embryos were harvested. Histological analysis of E16, Dox-
treated hearts revealed thinning in the atrial walls of the
Tg
 
 
 
 embryos as compared with their Wt littermates (Fig. 3
A). Both left and right atria of the Tg
 
 
 
 hearts exhibited
thinner walls and chamber dilation (Figs. 3 B). In contrast,
Dox-treated Tg
 
 
 
 and Wt ventricles exhibited similar wall
thickness, which might be due to incomplete inhibition of
calcineurin activity. In the absence of Dox, Tg
 
 
 
 and Wt
hearts were similar in appearance. Together, these data in-
dicate that inhibition of NFAT activity causes thinning in
the myocardium.
Previous papers demonstrated that administration of cy-
closporin A (CsA) from E0.5 causes malformation of blood
vessels at 
 
 
 
E8.5 (Graef et al., 2001). CsA blocks calcineurin
phosphatase activity and thus attenuates NFAT functions. We
tested whether administration of CsA, starting at E14 to by-
pass the early effect of CsA in vasculature malformation, causes
thinning of the myocardium (Fig. 3 C). CsA-treated hearts,
harvested at P0, exhibited thinner atrial walls as compared
with the control. CsA-treated ventricles also exhibited severe
myofiber disorganization. These data further indicate that in-
hibition of NFAT activity disrupts myocardium development.
 
The inhibitory effect of dnNFAT is mediated by suppres-
sion of calcineurin-mediated nuclear translocation of NFAT
(Aramburu et al., 1998; Chow et al., 1999; Miskin et
al.,  2000). Previous reports established that expression of
calcineurin causes cardiac hypertrophy and sudden death
(Molkentin et al., 1998). We tested whether expression of
calcineurin rescues thinning of the myocardium in dnNFAT
embryos. Heterozygous Tg
 
 
 
 male mice expressing dnNFAT
were crossed with Tg
 
 
 
 female mice expressing calcineurin.
Immunofluorescence analysis indicated that expression of
calcineurin promoted NFAT nuclear localization, even in
the presence of dnNFAT, in E16 and P0 hearts (Fig. 3 D).
Histological analysis indicated that Wt and calcineurin Tg
 
 
 
hearts exhibited similar atrial wall thickness (Fig. 3 E). Ex-
pression of dnNFAT reduced atrial wall thickness, and the
reduction was attenuated by the expression of calcineurin.
Thus, these data further indicate that NFAT activity is im-
portant for the developing myocardium.
 
Requirement of NFAT at later stages 
of myocardial development
 
To examine temporal regulation of NFAT in the develop-
ing myocardium, we determined the atrial wall thickness
of Dox-treated, Tg
 
 
 
 hearts that were harvested at various
embryonic stages (Fig. 4 A). Tg
 
 
 
 hearts harvested at E14
exhibited similar wall thickness and appearance as their
Wt littermates. However, Tg
 
 
 
 hearts harvested at E16
Figure 3. Inhibition of NFAT causes thinning of 
developing atrial walls. (A and B) Histological 
analysis of E16 atria. Timed-pregnant mice were 
given Dox-treated water ( ) or untreated, plain 
water ( ) from the day of conception (E0.5). Wt 
littermate control and Tg  embryos harvested from 
the same litter on E16 were fixed in 10% formalin 
and serial sectioned sagittally. Representative 
sections, collected from six embryos of multiple 
litters, were shown (A). Dox-treated Tg  atria 
exhibited thinner atrial walls as compared with their 
Wt littermates. Enlarged images to illustrate thinning 
of atrial walls were shown (B). RA, right atrium; 
LA, left atrium. Bars: low magnification, 200  m; 
high magnification, 60  m. (C) Administration 
of cyclosporin A (CsA) disrupts myocardium 
development. Wt pregnant mice were given CsA 
daily starting on E14. Control and CsA treated 
embryos were harvested on day of birth (P0). 
Sagittal sections of developing atria and ventricles 
were shown. (D and E) Expression of calcineurin 
(Cn) attenuates thinning of the atrial walls in dnNFAT 
mice. Heterozygous Tg  male mice expressing 
dnNFAT were crossed with Tg  female mice 
expressing calcineurin. Dox-treated embryos 
were harvested on E16 and day of birth (P0). 
Immunofluorescence analysis indicated localization 
of NFAT in the nuclei (yellow) in calcineurin-
expressing hearts (D). Histological analysis revealed 
that expression of calcineurin reduced thinning of 
myocardium in dnNFAT-expressing hearts (E). 
Bars: E16 hearts, 40  m; P0 hearts, 75  m.T
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showed reduced atrial wall thickness. Tg
 
 
 
 hearts har-
vested at E18 or P0 also exhibited reduced atrial wall
thickness. In the absence of Dox, E16 Tg
 
 
 
 and Wt hearts
exhibited similar wall thickness and appearance. Morpho-
metric analysis to determine the atrial wall thickness also
indicated a decrease in the Dox-treated Tg
 
 
 
 atria as com-
pared with their Wt littermates (Fig. 4 B). Unlike the
atria, Tg
 
 
 
 and Wt ventricles exhibited similar wall thick-
ness (Fig. 4 C). Together, these data demonstrate that
there is a reduction in the myocardium in hearts express-
ing dnNFAT after E14.
We further examined the temporal requirement for NFAT
at the later stages of the developing myocardium (Fig. 5 A).
Pregnant mice were exposed to Dox from E0 to E8 and then
were given untreated, plain water from E8 to E16. Tg
 
 
 
 and
Wt hearts, which were harvested on E16, exhibited similar
atrial wall thickness and appearance. However, E16 Tg
 
 
 
hearts that were exposed to Dox from E8 to E16 exhibited
thinner atrial walls as compared with their Wt littermates.
When Dox was withdrawn at E14 (i.e., Dox treatment from
E8 to E14), thinning of atrial walls was not observed on Tg
 
 
 
hearts harvested on E16. These data indicate that NFAT is
required at the later stages of myocardium development.
To directly examine the importance of NFAT between
E14 and E16, pregnant mice were gavage fed with Dox-
 
treated water on E14, and then drank Dox-treated water un-
til the embryos were harvested on E16 (Fig. 5 A). Histologi-
cal analysis of Tg
 
 
 
 embryos that were exposed to Dox for
2 d revealed thinner atrial walls as compared with their Wt
littermates. These data demonstrate that NFAT is required
for the developing myocardium after E14.
Next, we determined the requirement of NFAT between
E14 and P0 (Fig. 5 B). We examined whether administra-
tion of Dox after E14, when NFAT has already translocated
into the nucleus (Fig. 1), causes thin myocardium. Tg
 
 
 
 em-
bryos exposed to Dox from E16 to P0 or from E16 to E18,
exhibited thinner atrial walls as compared with their Wt lit-
termates. These data indicate that NFAT inhibition also
causes thin myocardium after E16.
We also determined whether thinning of the myocardium
is reversible. When Tg
 
 
 
 embryos were exposed to Dox for
two days from E14 to E16 and harvested at E18, their atrial
walls were thinner than the E18 Wt littermates (Fig. 5 B).
Newborn (P0) Tg
 
 
 
 pups that were exposed to Dox from
E16 to E18 exhibited thinner atrial walls as well. Therefore,
thinning of the myocardium is not reversible. Together,
these data demonstrate that NFAT is required continuously
between E14 and P0 for myocardium development.
 
Cell viability of the thin myocardium
 
Next, we examined whether apoptosis plays a role in the
thinning of the myocardium (Fig. 6 A). TUNEL assays were
performed to detect apoptotic cells from Dox-treated, E14
and E16, Tg
 
  
 
and Wt hearts. No apoptotic nuclei could be
detected in either Tg
 
 
 
 or Wt atria at E14 or E16. Control
showed an intense staining of nuclei with fragmented DNA.
In addition, the number of nuclei found in Tg
 
 
 
 and Wt
atria was similar (Fig. 6 B). Thus, thinning of the myocar-
dium in Tg
 
 
 
 heart is not due to the loss of cardiac myocytes.
 
Cytoarchitecture of the thin myocardium
 
Thinning of the myocardium may be due to defects in cy-
toskeletal and sarcomeric structure. Ultrastructural studies
revealed classic sarcomeric pattern with layers of mitochon-
dria between bands of connected myofilaments in the Wt
myocytes (Fig. 7). Periodic patterning of M and Z lines gen-
erated from overlapping thick and thin filaments was also
observed. However, the cytoarchitecture of Tg
 
 
 
 cardiac
myocytes was disrupted, in addition to the reduction in cell
thickness. There were varying degrees of sarcomere disorga-
nization, ranging from misalignment of fiber bundles and
random orientation of sarcomeres to complete loss of sar-
comere and mitochondrial patterning and disappearance of
Z lines. In the most severe case, only scattered individual fil-
aments were observed. These data indicate that the struc-
tural components of the myocardium are severely disrupted
in dnNFAT hearts.
 
Expression of cytoskeletal and sarcomeric proteins 
in Tg
 
 
 
 and Wt hearts
 
Disruption of sarcomere formation indicated that the struc-
tural components of cardiac myocytes are altered. We exam-
ined whether the expression level of cytoskeletal and sarco-
meric proteins were affected in Tg
 
 
 
 hearts (Fig. 8). Hearts
from multiple litters of Dox-treated embryos were harvested
Figure 3 continued.T
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at P0. Isolated hearts were further micro-dissected to sepa-
rate the atria from the ventricles. Whole-cell extracts gener-
ated from the pooled samples were subjected to immuno-
blotting analysis. The expression level of vinculin, desmin,
 
 
 
-actinin, actin, 
 
 
 
-myosin, and caveolin-3 was similar in Wt
and Tg
 
 
 
 atria (Fig. 8 A). The expression level of these pro-
teins in ventricles was also similar. Thus, these proteins do
not account for the disruption of sarcomere formation.
Next, we examined the expression level of the members of
the troponin complex (Fig. 8 B). Immunoblot analysis indi-
cated that tropomyosin and troponin-C expression levels
were similar in Tg
 
 
 
 and Wt atria and ventricles. The ex-
pression of slow skeletal troponin-I (ssTnI) and slow skeletal
troponin-T (ssTnT) were also similar. However, the expres-
sion level of cTnI and cTnT was reduced in the Tg
 
 
 
 atria as
compared with the Wt control. The expression level of cTnI
and cTnT was similar in Tg
 
 
 
 and Wt ventricles. These data
indicate that reduced expression of specific members of the
troponin complex may, in part, account for the disruption
of myocytes cytoarchitecture.
 
NFAT binding elements are present in the cTnI 
and the cTnT genes
 
Reduced cTnI and cTnT protein expression suggested that
NFAT might directly regulate transcription of these genes.
Sequence analysis indicated that there are putative NFAT
binding elements in the regulatory regions of the cTnI and
cTnT promoters (Fig. 9 A). The cTnI NFAT site is located
 
 
 
300 bp upstream of the transcriptional start site. The
cTnT NFAT sites are present in the first intron, which is lo-
cated between the 5
 
 
 
-untranslated region (exon 1) and the
ATG translational start site (exon 2). We performed electro-
phoretic mobility shift assays to test whether these putative
binding elements interact with NFAT. Electrophoretic mo-
bility shift assays revealed formation of specific NFAT–
DNA complexes (Fig. 9 B). Incubation with NFAT anti-
Figure 4. Temporal requirement of NFAT in 
atrial development. (A) Timed-pregnant mice were 
given Dox-treated water (filled bars) from the day 
of conception (E0). Wt littermate control and Tg  
embryos were harvested (arrows) on E14, E16, or 
day of birth (P0). Harvested embryos were fixed 
in 10% formalin and serial sectioned sagittally. 
Representative sections, collected from six embryos 
of multiple litters, were shown. Thinning of atrial 
walls was only found in Dox-treated Tg  hearts, harvested on E16, and P0 embryos. Tg  embryos harvested from pregnant mice that drank 
untreated, plain water (shaded bars) exhibited similar atrial wall thickness as compared with the Wt control. The interval of nuclear NFAT 
was also indicated (red bar). Bar, 50  m. (B and C) Morphometric analysis of the developing atria. Cross-sectional thickness of atrial (B) and 
ventricular (C) walls, from six embryos, was measured. Reduction in atrial wall thickness was found in Dox-treated Tg  embryos on E16 
or later. However, Wt and Tg  ventricles exhibited similar thickness. Embryos that were not exposed to Dox also exhibited similar wall 
thickness. RA, right atria; LA, left atria; RV, right ventricles; LV, left ventricles.T
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body either abolished formation or caused supershift of the
NFAT–DNA complexes. These data indicate that NFAT
binds to the cTnI and cTnT gene promoters.
Further, we performed competition analysis to examine
NFAT binding on cTnT and cTnI NFAT elements. Excess
amount of the Wt (but not the mutated) NFAT binding el-
ements abolished formation of NFAT–DNA complexes
(Fig. 9 C). Canonical NFAT binding elements from the
IL-2 and the peroxisome proliferator–activated receptor 
 
 
 
2
(PPAR
 
 
 
2; proximal and distal) genes also reduced, although
to different extents, formation of cTnT or cTnI NFAT–
DNA complexes (Fig. 9 D). Previous reports indicated that
the canonical NFAT element from the IL-2 gene binds
NFAT and AP-1 (Fos and Jun) while C/EBP is present in
the PPAR
 
 
 
2 proximal NFAT site. The different degree of
competition on the cTnT site 1, cTnT site 2, and cTnI
NFAT elements suggested formation of distinctive NFAT
complexes. Thus, different NFAT complexes may bind to
the cTnT and cTnI genes.
We also examined NFAT regulation of the cTnI gene in
different species. Sequence alignment indicated that similar
NFAT-binding elements are located in the human, rat, and
mouse cTnI genes (Ausoni et al., 1994; Bhavsar et al., 1996,
2000; Murphy et al., 1997; Di Lisi et al., 1998; Fig. 9 A).
Importantly, the sequence similarity extends to the adja-
cent nucleotides, suggesting interaction with a comparable
NFAT partner for regulating cTnI gene expression. Electro-
phoretic mobility shift assays revealed cross competition
among the different cTnI NFAT elements (Fig. 9 E). Com-
petition with other canonical NFAT elements also reduced
formation of the mouse cTnI NFAT complex to different
degrees. These data indicate similar regulation of the cTnI
gene transcription by NFAT.
 
NFAT regulates the cTnI and the cTnT gene promoters
 
Next, we performed luciferase reporter gene assays to exam-
ine whether NFAT regulates transcription of the cTnI and
the cTnT genes (Fig. 10 A). The cTnI promoter (
 
 
 
1 to
Figure 5. Requirement of NFAT at later stages of atrial development. Pregnant mice were given and taken off Dox-treated water (filled bars) 
at various times during gestation. The duration that pregnant mice drank untreated, plain water (shaded bars) was also indicated. Wt littermate 
control and Tg  embryos were harvested on date indicated (arrows). Harvested embryos were fixed in 10% formalin and serial sectioned 
sagittally. Representative sections, collected from six embryos of multiple litters, were shown. Thinning of atrial walls was found in E16 hearts 
that were exposed to Dox, from E14 to E16, for even 2 d (A). NFAT activity is required continuously from E16 to P0, and thinning of the atrial 
walls is irreversible (B). The interval of nuclear NFAT was also indicated (red bar). Bars, 50  m.T
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 303) was subcloned upstream of a luciferase reporter gene.
The cTnI luciferase reporter was cotransfected with either
constitutive active calcineurin ( Cn) or constitutive nuclear
NFATc4 (cnNFATc4; Fig. 10 B). Coexpression of either
 Cn or cnNFATc4 increased cTnI reporter gene activity.
Importantly, deletion to  283, to remove the cTnI NFAT
binding site, or mutation at the NFAT binding sequence,
abolished NFAT-mediated gene transcription (Fig. 10 C). A
luciferase reporter plasmid containing a triple repeat of the
cTnT site 1 NFAT element was also examined (Fig. 10 D).
Coexpression of either  Cn or cnNFATc4 increased cTnT
reporter gene activity. Together, these data indicate that
NFAT binds to and regulates cTnI and cTnT gene expres-
sion. Regulation of cTnI and cTnT gene expression by
NFAT may, in part, account for the structural architecture
of the developing myocardium.
Discussion
Requirement for NFAT in the heart
The transcription factor NFAT plays an important role in cy-
tokine gene expression (Rao et al., 1997; Crabtree, 1999).
NFAT was once thought as being a specific regulator in im-
mune cells. However, recent papers have proposed that NFAT
is a ubiquitous regulator for cell growth, differentiation, and
apoptosis (Horsley and Pavlath, 2002). In this report, we dem-
onstrate that NFAT regulates transcription of cTnI and cTnT
genes and plays a critical role in the structural architecture of
the developing myocardium. Thus, our data provide new evi-
dence to expand the repertoire of functions of NFAT.
In this paper, we show that NFAT activity is required in
the myocardium between E14 and P0. Previous gene-target-
ing studies indicated that NFATc1 is required in the en-
docardium between E7.5 to E13.5 for heart valve develop-
ment (de la Pompa et al., 1998; Ranger et al., 1998),
whereas NFATc3 and NFATc4 are important in endothelial
cells for vasculature formation between E7.5 and E8.5
(Graef et al., 2001). Administration of CsA at the early stage
(before E10.5) of cardiac morphogenesis also affects vascula-
ture formation. In this report, we show that late administra-
tion of CsA (starting on E14) causes thin myocardium and
myofiber disorganization. Thus, the role of NFAT in heart
development is spatially and temporally regulated. In addi-
tion, different NFAT members seem to differentially regu-
late these functions. Future studies to examine the temporal
interval of activation and the expression profile of different
members will be critical to understand the biological func-
tions mediated by NFAT.
In this report, we demonstrate that inhibition of NFAT
activity by expression of dnNFAT causes thinning of atrial
walls. Kinetics of dnNFAT induction and disinhibition is
critical to reveal when NFAT activity is required. Our data
Figure 6. Cell viability of the developing mouse atria. (A) TUNEL assays were performed to examine cell viability in Dox-treated developing 
mouse atria. As compared with control, which show an intense staining of fragmented DNA in apoptotic cells, TUNEL-positive cells were not 
detected at E14 and E16 Wt littermate and Tg  atria, Bar, 50  m. (B) The number of myocyte nuclei is similar. The number of intact nuclei in 
the Wt and the Tg  atria was counted every 0.3 mm along the atrial wall and illustrated. RA, right atria; LA, left atria.T
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indicated that a 2-d administration of Dox, between E14
and E16, to induce dnNFAT is sufficient to cause thin myo-
cardium. Because there is an uncertainty of time of concep-
tion, ranging from 8–12 h (Kaufman, 1992; Kaufman and
Bard, 1999), and a lag time for transcription, translation,
and subsequent accumulation of rtTA and dnNFAT, which
is at least 8 h (Kistner et al., 1996; Akagi et al., 2001;
Gunther et al., 2002; Ohno-Matsui et al., 2002; Perl et al.,
2002), we believe that the examination of hearts at a 2-d in-
terval should closely represent the temporal requirement of
NFAT during development.
Conversely, withdrawal of Dox on E14, after 6 d of Dox
treatment, before harvesting hearts on E16 (i.e., 2 d with-
out Dox before examination of hearts) does not produce
thinner atria. These data suggest a rapid loss of the inhibi-
tory effect. The loss of inhibition may be due to a high
turnover of dnNFAT, rtTA, or Dox. Alternatively, a sub-
stantial expression of endogenous calcineurin may also con-
tribute to the efficient disinhibition. The inhibitory effect
of dnNFAT is to act as a “sink” to interact with cal-
cineurin, and hence, blocks endogenous NFAT functions
(Northrop et al., 1994; Aramburu et al., 1998; Chow et al.,
1999; Miskin et al., 2000; Saneyoshi et al., 2002). If there
were insufficient accumulation of dnNFAT, calcineurin-
mediated NFAT functions would remain active, which
may account for the lack of effect of dnNFAT in develop-
ing ventricles. However, treatment with CsA to inhibit
Figure 7. Cytoarchitecture of the developing mouse atria. 
Ultrastructure of P0 atria was examined by transmission electron 
microscopy. Electron micrographs revealed characteristic banding 
pattern of sarcomere in Dox-treated Wt littermate control. 
Mitochondria layered between myofilaments were also observed. 
However, Dox-treated Tg  atria displayed severely perturbed 
sarcomere and mitochondria. Varying degrees of sarcomeric 
disorganization were also observed. Cross-sectional cell thickness of 
Wt and Tg  atria was shown (A). Low (A) and high (B) magnifications 
of Wt and Tg  atria are presented. Bar, 1  m.
Figure 8. Expression of cytoskeletal and sarcomeric proteins in 
Tg  and Wt hearts. Dox-treated embryos were harvested on P0, 
micro-dissected to separate atria and ventricles, and genotyped. 20 
Wt or Tg  atria (or 10 ventricles) were collected from multiple 
litters, homogenized, and extracts obtained were separated on 
SDS-PAGE. Immunoblots were performed with vinculin, desmin, 
 -actinin, actin, myosin, and caveolin-3 antibodies (A). Expression 
of tropomyosin, troponin-C, ssTnI, ssTnT, cTnT, and cTnT were also 
examined (B).T
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NFAT activity causes myofiber disarray in addition to the
thinning of the atrial wall, supporting a critical role of
NFAT in the developing ventricles. Thus, a threshold for
dnNFAT inhibition is a balance of expression between dn-
NFAT, rtTA, and calcineurin.
Previous papers indicated that NFAT plays an important
role in the calcineurin signaling pathway in cardiac hyper-
trophy (for reviews see Molkentin and Dorn, 2001; Sug-
den, 2001; Frey and Olson, 2003). Cardiac hypertrophy is
an adaptive response to increase workload on physiological
and pathological demand. Molecular analysis indicates reac-
tivation of a fetal gene expression program during cardiac
hypertrophy; for example, increased expression of atrial
natriuretic factor in hypertrophic ventricular muscle. Thus,
calcineurin activation during cardiac hypertrophy may cor-
relate with the role of NFAT in developing myocardium to
regulate gene expression. Expression profiling studies to de-
termine common molecular targets of NFAT in developing
myocardium and in hypertrophic hearts will shed new light
on the role of calcineurin signaling in heart development
and function.
NFAT-mediated gene transcription in the heart
Different isoforms of various sarcomeric proteins are differ-
entially expressed in the developing and adult heart (Perry,
1998, 1999). In early embryonic stages, ssTnI is expressed,
but eventually is replaced by cTnI, which is the predomi-
nant isoform in neonates and adult mice (Saggin et al.,
1989; Gorza et al., 1993). Similarly, ssTnT is expressed in
the embryonic heart, but is replaced by cTnT at later stages
(Saggin et al., 1988; Wang et al., 2001). A critical time for
the switch over of these TnT and TnI isoforms would be at
or around birth, in order to prepare for the increased work-
load in neonates when all the major organs are fully devel-
oped and the circulation system becomes independent. Re-
duced structural integrity by NFAT inhibition and increased
hemodynamics at the later developing stages may account
for the abrupt thinning of the myocardium. Thus, NFAT
may play a critical role in the switch over of troponin iso-
forms for the preparation of heart maturation.
Genomic analyses indicate that ssTnT and cTnI genes are
located in the same gene locus (Barton et al., 1999). Inter-
estingly, the cTnT and ssTnI genes are also closely linked.
Figure 9. NFAT-binding elements are 
presented in the cTnT and cTnI genes. 
(A) Sequence comparison of the NFAT-
binding sites found in IL-2, PPAR 2 
(proximal and distal), cTnT (sites 1 and 2), 
and cTnI gene promoters. NFAT-binding 
elements from the mouse and rat cTnI 
are also shown. Canonical NFAT-binding 
site is illustrated (filled box). Adjacent 
NFAT partner binding site is also indicated 
(AP-1, shaded box; C/EBP, hatched box). 
Residues on the cTnT and cTnI NFAT 
sites that resemble the AP-1 (*) or C/EBP 
(^) binding sequence are also indicated. 
Similar nucleotides found in human, 
rat, and mouse cTnI are underlined. 
(B and C) NFAT interacts with the cTnT- 
and cTnI-binding elements. Gel mobility 
shift assays were performed, in the 
presence ( ) or absence ( ) of NFAT 
antibody, to demonstrate specific 
interaction of NFAT to the cTnT- and 
cTnI-binding elements (B). Antibody-
supershifted complexes were also 
indicated. NFAT–DNA complexes were 
also competed by excess Wt, but not 
mutated, cTnT or cTnI oligonucleotides 
(C). (D) Formation of distinct NFAT 
complexes on the cTnT- and cTnI-binding 
elements. NFAT–DNA complexes were 
competed by using NFAT binding 
elements from the IL-2, the PPAR 2, and 
the cTnT genes as indicated. Differential 
competition by these canonical NFAT 
binding elements suggests formation 
of various NFAT–DNA complexes. 
(E) Comparison of NFAT complexes from 
the human, rat, and mouse cTnI NFAT 
elements. NFAT–DNA complexes were 
cross competed among different cTnI 
elements as indicated. Other canonical 
NFAT elements were also used to compete 
formation of NFAT complexes from the 
mouse cTnI NFAT element.T
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Chromatin remodeling and activation of the gene loci (e.g.,
histone acetylation and increase DNaseI hypersensitivity)
are likely involved in the switch over from ssTnT to cTnT
or ssTnI to cTnI during heart maturation. Previous reports
indicated that NFAT binds to DNaseI hypersensitive sites
and regulates the expression of several cytokine and PPAR 2
genes (Duncliffe et al., 1997; Agarwal et al., 2000; Ren et
al., 2002). Because induction of dnNFAT reduced cTnI and
cTnT (but not ssTnI and ssTnT) expression, it is possible
that temporally activated NFAT, in conjunction with differ-
ent NFAT partners, binds to the ssTnT/cTnI and the
cTnT/ssTnI gene loci to facilitate the switch over and allow
subsequent induction of cTnT and cTnI at or around birth.
NFAT was first identified as an important regulator in IL-2
gene expression (Jain et al., 1993; Northrop et al., 1993,
1994). Cooperative interaction between NFAT and AP-1
(Fos and Jun) is critical for expression of many cytokine genes
in immune cells. Analogous to the NFAT–AP-1 complex, we
have recently demonstrated that NFAT interacts with C/EBP
to mediate expression of the PPAR 2 gene in adipocytes
(Yang and Chow, 2003). Similarly, NFAT–C/EBP compos-
ite enhancer complex is found in the upstream regulatory re-
gion of the angiotensin-converting enzyme homologue gene
(ACEH/ACE2), which is induced at E15 and becomes highly
expressed at E17 in the mouse embryo (Crackower et al.,
2002). Recent gene-targeting studies indicate that ACE2-null
mice exhibit thin myocardium, whereas ACE2 mutant flies
display heart defects (Crackower et al., 2002). In addition, a
balance of ACE2 and ACE activity is proposed to regulate he-
modynamics through the renin–angiotensin system (Eriksson
et al., 2002; Turner and Hooper, 2002). Thus, it is tempting
to speculate that besides structural proteins, NFAT regulates
ACE2 expression during embryonic development and in
pathophysiological hearts to modulate myocardium forma-
tion, and mediates compensatory response during hyperten-
sion and/or hypertrophy, respectively.
In addition to AP-1 and C/EBP, GATA and MEF2 tran-
scription factors also interact with NFAT to mediate gene
expression (Molkentin et al., 1998; Musaro et al., 1999;
Blaeser et al., 2000; Wu et al., 2000). Thus, NFAT forms
a distinctive composite enhancer complex with different
NFAT partners to mediate gene transcription. In this report,
we show that NFAT binds to the cTnT and cTnI promot-
ers. Importantly, the NFAT element is located in the mouse
minimal cTnI promoter, which directs transgene expression
in the developing cardiac atrioventricular canal (Di Lisi et
al., 1998, 2000), supporting a role of NFAT in cardiac de-
velopment. However, competition analysis indicates that
different NFAT–DNA complexes are formed. These differ-
ent NFAT complexes may represent additional regulation
by NFAT (and its partners) in mediating multiple biological
functions. Further identification of these NFAT partners
will be important to understand the molecular basis of
NFAT-mediated gene transcription.
In conclusion, we have demonstrated that NFAT is tem-
porally and spatially required for the developing myocar-
dium. Identifying the role of NFAT in the developing myo-
cardium expands the repertoire of functions of NFAT.
Materials and methods
Reagents
The expression vectors for calcineurin, NFATc4, tetracycline-inducible
system have been described previously (Gossen et al., 1995; Hoey et al.,
1995; Ray et al., 1997; Yang et al., 2002). Sequence for the cTnI and cTnT
genes have been reported previously (GenBank/EMBL/DDBJ accession
nos. X90780 and AY044273). The cTnI promoters were amplified from ge-
nomic DNA and subcloned into the pGL3 basic luciferase reporter plas-
mid using MluI and XhoI sites. Antibodies against NFATc2 (#sc-7295),
NFATc4 (#sc-13036), desmin (#sc-7559), vinculin (#sc-7649), cTnI (#sc-
8118), and cTnT (#sc-8121) were obtained from Santa Cruz Biotechnol-
ogy, Inc. The pan-NFAT antibody (#796) was a gift from Dr. Nancy Rice
(National Cancer Institute, Fredrich, MD; Lyakh et al., 1997). The M2 mAb
(#F3165) and the  -actinin (#A7811), actin (#A2172), and tropomyosin
(#T3691) antibodies were obtained from Sigma-Aldrich. Caveolin-3 anti-
body (#C38320) was obtained from Transduction Laboratories. The tropo-
nin-C antibody (#HG2a) was obtained from Advanced Immunochemicals.
The  -myosin antibody (#MF20) was obtained from the Developmental
Studies Hybridoma Bank (University of Iowa, Iowa City, IA).
Mice
Conditional transgene expression in cardiovascular system has been de-
scribed previously (Yu et al., 1996). Two transgenes were constructed: (1)
the   -MHC promoter (a gift from Dr. Jeff Robbins, Children’s Hospital
Medical Center, Cincinnati, OH; Subramaniam et al., 1991) was sub-
cloned upstream of the tetracycline-regulator (rtTA; a gift from Dr. Prabir
Ray, University of Pittsburgh, Pittsburgh, PA; Ray et al., 1997); and (2) the
DNA fragment encoding FLAG-tagged dnNFAT (Chow et al., 1999) was
subcloned downstream of the Tet-O promoter (Ray et al., 1997). Both
transgenes (in 1:1 molar ratio) were injected simultaneously into pronuclei
Figure 10. NFAT regulates the cTnI and the cTnT gene promoters. 
cTnI promoter (cTnI,  1 to  303 and  1 to  283) was subcloned 
upstream of a luciferase reporter gene (A). Mutation at the cTnI 
NFAT element was also shown. Constitutive active calcineurin 
( Cn, shaded bars) or constitutive nuclear NFATc4 (cnNFATc4, 
filled bars) was cotransfected with the cTnI luciferase reporter 
plasmid (B and C). Cells were harvested 36 h after transfection. 
Luciferase and  -galactosidase activities were measured. Luciferase 
reporter plasmid containing a triple repeat of the cTnT site 1 NFAT 
element was also examined similarly (D). Filled ovals represent 
NFAT binding sites.T
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of pseudo-fertilized eggs to generate transgenic mice. Two inducible Tg 
founders (line #3 and 8) were established and backcrossed onto C57BL/6
mice (The Jackson Laboratory). Genotyping analysis indicated that both
transgenes were cointegrated and cosegregated together. Littermates from
line #3 were used for further analysis.
Timed-pregnant mice were injected intraperitoneally with 25 mg/kg CsA
daily starting at E14. Control mice received DMSO. Embryos were har-
vested on P0 and hearts were prepared. Representative sections were hema-
toxylin- and eosin-stained and were examined under a microscope (model
IX70; Olympus).
Immunofluorescence analysis
Paraffin-embedded sections from E14 and E16 Tg  and Wt hearts were
deparaffinized and rehydrated through a series of graded alcohol and PBS
washes. Rehydrated sections were incubated in blocking solution (2% goat
serum and 0.1% Triton X-100 in PBS) for 20 min. The sections were then
washed twice in wash buffer (0.1% Triton X-100 in PBS) and incubated
with indicated primary antibody (diluted 1:100 in the blocking solution)
overnight at 4 C. After washing three times in wash buffer (10 min each),
the sections were incubated with the appropriate FITC-conjugated second-
ary antibody (diluted 1:500 in the blocking solution) for 45 min. The sec-
tions were then washed for 30 min, and counterstained with 10  g/ml of
bis-benzimide (Sigma-Aldrich) for 15 min to detect DNA. After a final
wash for 20 min, a coverslip was mounted on the slides with ProLong
® An-
tifade (Molecular Probes, Inc.). Sections were analyzed and images were
generated using an inverted microscope (model IX70; Olympus) and a 12-
bit cooled CCD camera (Sensi Cam GE; Photometrics). Images of antibody
staining and nuclei counterstaining were deconvolved using I.P. Lab Spec-
trum software and merged into one image using Adobe Photoshop
®. Inten-
sity of NFAT nuclear staining was determined by using Adobe Photoshop
®
and NIH Image software.
Embryonic heart preparation
Embryonic hearts were harvested at various times during gestation as in-
dicated. The date after conception was registered as E0.5. On the day of
harvest, the embryos were decapitated and the hind limbs were removed
for genotyping. The remaining torso was fixed in 10% buffered formalin
overnight before isolation of the hearts through a dissecting microscope
(model SV11; Carl Zeiss MicroImaging, Inc.). Isolated hearts were then
rinsed in PBS and dehydrated through a graded series of alcohol washes.
After washing three times in xylene (10 min each), isolated hearts were
immersed in paraffin (three times, 15 min each), oriented, and embed-
ded. Embedded hearts were serially sectioned sagittally at a thickness of
7  m using a microtome (Microm; Baxter Scientific), and were placed on
super-frost plus slides (Fisher Scientific). Representative sections were he-
matoxylin- and eosin-stained and examined under a microscope (model
IX70; Olympus).
Expression of dnNFAT
4-wk-old double Tg  or Wt nontransgenic littermate mice were given ei-
ther untreated, plain water or Dox-treated water (2 mg/ml) for 1 wk before
isolation of their hearts. The hearts were removed, homogenized, and iso-
lated cell extracts were separated on an SDS-PAGE (12%). Expression of
dnNFAT was examined by immunoblotting analysis using the M2 mAb
that recognizes the FLAG epitope.
Morphometric analysis
To determine atrial and ventricular wall thickness, digital images of Tg 
and Wt hearts harvested on different dates of gestation (E14, E16, E18, and
P0) were generated. Nine individual fields from each heart were taken as
separate images. Using NIH Image software (National Institutes of Health,
Bethesda, MD), wall thickness was measured at eight different locations
from each image and an average was taken from six embryos, which were
derived from three different litters. The averages (i.e., 432 data points per
condition) were then input into Sigma Plot and graphed.
To determine myocyte nuclei count, image photos were randomly
taken from E14 and E16 Tg  and Wt hearts (40x magnification). Nine pho-
tos, from three different hearts, of each condition were produced and the
number of myocyte nuclei in the atrial walls was counted. The averages
were then input into SigmaPlot
® (SPSS, Inc.) and graphed.
To determine individual cell thicknesses, 40 low magnification elec-
tron micrographs, with multiple cells per micrograph, were generated.
Cell width at multiple points of each cell, from Wt or Tg  atria, was mea-
sured. The averages for each condition were then input into SigmaPlot
®
and graphed.
TUNEL stainings
Paraffin sections were deparaffinized as described earlier in Materials and
methods, and TUNEL staining was performed with the TACS™ 2 kit as recom-
mended by the manufacturer (Trevigen, Inc.). Sections were examined using a
microscope (Axiophot; Carl Zeiss MicroImaging, Inc.) and photographed.
Electron microscopy
Newborn pups (P0) were killed by decapitation, and their hearts were re-
moved. Hind limbs from the embryos were also removed for genotyping.
Isolated hearts were rinsed in PBS and fixed in 2.5% glutaraldehyde in 0.1 M
sodium cacodylate buffer for 4 h before processing for electron microscopy.
Protein immunoblotting
Newborn pups (P0) were killed by decapitation, and micro-dissection was
performed to separate atria and ventricles. Hind limbs from the embryos
were also removed for genotyping. 20 Tg  or Wt atria (or 10 ventricles)
were collected from multiple litters, homogenized in 1 ml 3  SDS sample
buffer (140 mM Tris, pH 6.8, 5% glycerol, 2% SDS, 0.1 M DTT, and 30
 M bromophenol blue), and boiled. Sample was cleared by centrifugation,
and the amount of protein was determined by Ponceau-S staining. An
equal amount of protein from Wt and Tg  atria and ventricle was resolved
on SDS-PAGE (8% or 12%), and was electrotransferred to nitrocellulose
membranes (Millipore). Immunoblotting analysis was performed to deter-
mine the expression level of various cytoskeletal or sarcomeric proteins.
Gel mobility shift assays
Double-stranded oligonucleotides encoding NFAT-binding sites from the
cTnI gene promoter (5 -AGT CTG AGG GAA AAG GGG GCT GGG-3 )
and the cTnT gene promoter (site 1, 5 -GAG TGG ATG GAA AGG TTG
AGA AAC TGC AGA-3 ; and site 2, 5 -TGG CTT AGG AAA ATC CCA TTC
GAG TGC TGG-3 ) were labeled with  [
32P]dCTP and used as probes. Nu-
clear extracts prepared from NFATc4-transfected COS cells were used. Gel
mobility shift assays were performed as described previously (Yang and
Chow, 2003). For competition analysis, 10 pmol of unlabeled oligonucle-
otides (IL-2 NFAT, 5 -AGA AAG GAG GAA AAA CTG TTT CAT ACA GAA
GG-3 ; PPAR 2 proximal NFAT, 5 -ATTACAGGGAAAATATTGCCA-
CACTGTCTC-3 ; PPAR 2 distal NFAT, 5 -AGC AAG AGA TTT AAG TTT
TCC ATT TAA GAA-3 ; mouse cTnI, 5 -CTC AAA CTT AGG AAA ACC
CGG AGC AAG GTC-3 ; and rat cTnI, 5 -TTT AGA CTC AGG AAA ACC
CAG TAG CAA GGT-3 ) were incubated with the labeled probe before ad-
dition of nuclear extract.
Luciferase assays
The cTnI and cTnT promoter luciferase reporter constructs were cotrans-
fected into BHK cells with either  Cn or a cnNFAT construct. pRSV  -galac-
tosidase plasmid was also cotransfected as a control. Luciferase assays
were performed as described previously (Yang et al., 2002). The data are
presented as relative luciferase activity, calculated as the ratio of the lu-
ciferase activity to the activity of  -galactosidase (mean   SD; n   4]).
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